The American Journal of Medicine Supplements 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Streptococcus pneumoniae and community-acquired pneumonia: A cause for concern
Publication date: 2 August 2004 Source:The American Journal of Medicine Supplements, Volume 117, Issue 3, Supplement 1 Author(s): Thomas M File Jr. Community-acquired pneumonia (CAP) is the sixth most common cause of death in the United States and the leading cause of death from infectious diseases. It is associated with significant morbidity and mortality, and poses a major economic burden to the healthcare system. Streptococcus pneumoniae is the leading cause of CAP. Other common bacterial causes include Haemophilus influenzae as well as atypical bacteria (Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella ...
Source: The American Journal of Medicine Supplements - November 6, 2014 Category: Drugs & Pharmacology Source Type: research
Acute bacterial rhinosinusitis: Clinical impact of resistance and susceptibility
This article discusses a Sinusitis Therapeutic Outcome Model, a data-driven model used in the development of the treatment guidelines, with respect to different scenarios involving ABRS to illustrate the implications of antimicrobial selection on therapeutic outcome. (Source: The American Journal of Medicine Supplements)
Source: The American Journal of Medicine Supplements - November 6, 2014 Category: Drugs & Pharmacology Source Type: research
Treatment of acute bacterial rhinosinusitis caused by antimicrobial-resistant Streptococcus pneumoniae
Publication date: 2 August 2004 Source:The American Journal of Medicine Supplements, Volume 117, Issue 3, Supplement 1 Author(s): Jack B Anon Acute bacterial rhinosinusitis (ABRS) is a secondary bacterial infection of the nose and paranasal sinuses, usually preceded by a viral upper respiratory infection or allergy, with symptoms that have not improved after 10 days or that have worsened after 5 to 7 days. Streptococcus pneumoniae and Haemophilus influenzae are the most common causes of ABRS in adults. Increasing rates of antimicrobial resistance among S pneumoniae and β-lactamase production among H influenzae are fo...
Source: The American Journal of Medicine Supplements - November 6, 2014 Category: Drugs & Pharmacology Source Type: research
Overview of newer antimicrobial formulations for overcoming pneumococcal resistance
Publication date: 2 August 2004 Source:The American Journal of Medicine Supplements, Volume 117, Issue 3, Supplement 1 Author(s): William A Craig The pharmacokinetic (PK) and pharmacodynamic (PD) profile of an antimicrobial agent provides important information that can be used to maximize bacteriologic and clinical efficacy, minimize selective pressure for the development of antimicrobial resistance, and determine an optimal dosing regimen. Judicious selection of an antimicrobial based on local susceptibility data and PK and PD parameters is imperative in this era of increasing resistance among Streptococcus pneumonia...
Source: The American Journal of Medicine Supplements - November 6, 2014 Category: Drugs & Pharmacology Source Type: research
Streptococcus pneumoniae: Epidemiology and patterns of resistance
Publication date: 2 August 2004 Source:The American Journal of Medicine Supplements, Volume 117, Issue 3, Supplement 1 Author(s): Michael R Jacobs Streptococcus pneumoniae is a leading cause of bacterial pneumonia, meningitis, otitis media, and sinusitis; it results in significant morbidity and mortality in patients with pneumonia and meningitis. The pneumococcus is a common colonizing bacterium in the respiratory tract; it is especially common in the respiratory tracts of children, where it is frequently exposed to antimicrobial agents. This exposure can lead to resistance. Penicillin nonsusceptibility is found in n...
Source: The American Journal of Medicine Supplements - November 6, 2014 Category: Drugs & Pharmacology Source Type: research
CME-back
Publication date: 6 September 2004 Source:The American Journal of Medicine Supplements, Volume 117, Issue 5, Supplement 1 (Source: The American Journal of Medicine Supplements)
Source: The American Journal of Medicine Supplements - November 6, 2014 Category: Drugs & Pharmacology Source Type: research
Will eradication of Helicobacter pylori infection influence the risk of gastric cancer?
Publication date: 6 September 2004 Source:The American Journal of Medicine Supplements, Volume 117, Issue 5, Supplement 1 Author(s): Richard H. Hunt Gastric adenocarcinoma is a disease of high mortality and poor prognosis that is second only to lung cancer as a leading cause of cancer-related deaths worldwide. Although gastric cancer has a multifactorial etiology, infection with Helicobacter pylori is highly associated with its development. New information on bacterial and host genetics and results of epidemiologic studies suggest that better identification of individuals at high risk for gastric malignancy may be pos...
Source: The American Journal of Medicine Supplements - November 6, 2014 Category: Drugs & Pharmacology Source Type: research
Barrett esophagus: Will effective treatment prevent the risk of progression to esophageal adenocarcinoma?
Publication date: 6 September 2004 Source:The American Journal of Medicine Supplements, Volume 117, Issue 5, Supplement 1 Author(s): Prateek Sharma Barrett esophagus is a complication of long-standing gastroesophageal reflux disease (GERD) and is the well-recognized premalignant condition for the majority of esophageal and gastroesophageal junction adenocarcinomas. Although duration of gastroesophageal reflux (GER), male sex, and, possibly, a strong family history are directly related to risk of Barrett esophagus, the role of screening in those with GERD and surveillance in those with confirmed Barrett syndrome remain...
Source: The American Journal of Medicine Supplements - November 6, 2014 Category: Drugs & Pharmacology Source Type: research
Cardioprotective effects and gastrointestinal risks of aspirin: Maintaining the delicate balance
Publication date: 6 September 2004 Source:The American Journal of Medicine Supplements, Volume 117, Issue 5, Supplement 1 Author(s): Michael B. Kimmey Aspirin is a very useful medication for the prevention of cardiovascular thrombotic events in patients with or those at risk for cardiovascular disease (CVD). Aspirin, however, carries an increased risk for gastrointestinal (GI) injury (e.g., ulceration) and its complications (e.g., hemorrhage), which may be caused by its antiplatelet and gastric mucosal effects. In those with established CVD, aspirin use has been documented to decrease the risk of a first myocardial in...
Source: The American Journal of Medicine Supplements - November 6, 2014 Category: Drugs & Pharmacology Source Type: research
Prevention of nonsteroidal anti-inflammatory drug–associated gastrointestinal symptoms and ulcer complications
Publication date: 6 September 2004 Source:The American Journal of Medicine Supplements, Volume 117, Issue 5, Supplement 1 Author(s): David A. Peura Nonsteroidal anti-inflammatory drugs (NSAIDs) produce symptoms of dyspepsia and peptic ulcer disease in up to 50% and up to 20%, respectively, of individuals taking them. Risk factors for NSAID-related gastric injury include age >70 years, history of ulcer disease, use of multiple agents (e.g., ≥2 NSAIDs, or an NSAID plus aspirin—even at cardioprotective doses), high doses of an NSAID, and concurrent use of corticosteroids or anticoagulants. In NSAID users, infe...
Source: The American Journal of Medicine Supplements - November 6, 2014 Category: Drugs & Pharmacology Source Type: research
Extraesophageal symptoms: What role for the proton pump inhibitors?
Publication date: 6 September 2004 Source:The American Journal of Medicine Supplements, Volume 117, Issue 5, Supplement 1 Author(s): H.Juergen Nord The esophageal complications of gastroesophageal reflux disease (GERD) are well described and include erosive esophagitis, stricture, Barrett esophagus, and adenocarcinoma. Primary care physicians often encounter patients with “extraesophageal” manifestations of GERD in the absence of heartburn. Patients may present with symptoms involving the pulmonary system, noncardiac chest pain, and ear, nose, and throat disorders. The diagnosis of reflux disease in these individu...
Source: The American Journal of Medicine Supplements - November 6, 2014 Category: Drugs & Pharmacology Source Type: research
Managing gastroesophageal reflux disease for the lifetime of the patient: Evaluating the long-term options
Publication date: 6 September 2004 Source:The American Journal of Medicine Supplements, Volume 117, Issue 5, Supplement 1 Author(s): David C. Metz Lifetime management goals of gastroesophageal reflux disease (GERD) are to control esophageal as well as extraesophageal symptoms, maintain a stable noninflamed esophageal mucosa, and prevent complications. Large randomized clinical trials and >16 years of worldwide experience have confirmed the high rate of efficacy and excellent safety profile of proton pump inhibitor (PPI) therapy in individuals with all grades of GERD, making these agents the mainstay of treatmen...
Source: The American Journal of Medicine Supplements - November 6, 2014 Category: Drugs & Pharmacology Source Type: research
Management of acid-related disorders in patients with dysphagia
Publication date: 6 September 2004 Source:The American Journal of Medicine Supplements, Volume 117, Issue 5, Supplement 1 Author(s): Colin W. Howden Dysphagia affects a large and growing number of individuals in the United States, particularly the elderly and those who are neurologically impaired. Swallowing difficulties may be due to age-related changes in oropharyngeal and esophageal functioning as well as central nervous system diseases such as stroke, Parkinson disease, and dementia. Among institutionalized individuals, dysphagia is associated with increased morbidity and mortality. An appreciation of the physiolo...
Source: The American Journal of Medicine Supplements - November 6, 2014 Category: Drugs & Pharmacology Source Type: research
Endoscopy-negative reflux disease: Concepts and clinical practice
Publication date: 6 September 2004 Source:The American Journal of Medicine Supplements, Volume 117, Issue 5, Supplement 1 Author(s): William D. Chey Endoscopy-negative reflux disease is used to describe a heterogeneous group of disorders with symptoms that mimic those of gastroesophageal reflux disease in the absence of visible esophageal injury at endoscopy. Compared with patients who have gastroesophageal reflux–related erosive esophagitis, those with endoscopy-negative disease are more likely to be younger, female, of lower body weight, and without a hiatal hernia. Approximately 50% of those with endoscopy-negati...
Source: The American Journal of Medicine Supplements - November 6, 2014 Category: Drugs & Pharmacology Source Type: research
Appropriate strategies for testing and treating Helicobacter pylori in children: When and how?
Publication date: 6 September 2004 Source:The American Journal of Medicine Supplements, Volume 117, Issue 5, Supplement 1 Author(s): Philip M. Sherman Helicobacter pylori infection is acquired primarily during childhood and carries a significant lifetime risk for morbidity. In developing countries, approximately 70% of children are infected with the bacterium by their 15th birthday. In the United States, the rate of H pylori infection among children varies widely—approximately 10% of all 10-year-olds are infected; however, this figure is substantially higher among populations of immigrant children and children born...
Source: The American Journal of Medicine Supplements - November 6, 2014 Category: Drugs & Pharmacology Source Type: research
